Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Vizsgálat
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
2026. nov. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.
2026. nov. 1.· Hematological oncology· PUBMED
Publikáció
Structure-guided identification and functional evaluation of small-molecule candidates predicted to target the LAG-3/MHC-II interface.
2026. okt. 24.· Bioorganic chemistry· PUBMED
Publikáció
CTLA-4/PD-1, LAG-3, and TIGIT Inhibitors: Emerging Drug Targets and Combination Strategies in Hepatocellular Carcinoma.
2026. okt. 20.· Current cancer drug targets· PUBMED
Vizsgálat
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
2026. okt. 1.· PHASE1 · WITHDRAWN· CTGOV
Publikáció
Impact of obesity on LAG-3 and CTLA-4 expression in CD4+ T cells from lymph nodes of sarcoidosis patients.
2026. szept. 25.· Immunobiology· PUBMED
Publikáció
Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer.
2026. szept. 15.· Medical oncology (Northwood, London, England)· PUBMED
Publikáció
Anti-LAG-3 antibody treatment initiated after symptom onset extends survival in ALS model mice.
2026. szept. 10.· Neuroscience research· PUBMED
Publikáció
LAG-3 in Diffuse Large B-Cell Lymphoma: Immunohistochemical Expression Patterns and Clinicopathological Correlations.
2026. szept. 5.· Journal of clinical medicine· PUBMED
Vizsgálat
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
2026. aug. 31.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
2026. júl. 10.· Nature medicine· PUBMED
Publikáció
LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy.
2026. júl. 1.· Frontiers in oncology· PUBMED
Publikáció
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.
2026. júl. 1.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Melanoma cell-derived LAG-3 enhances CXCL1/8-driven MDSCs recruitment and immune escape via TRIM28-mediated IκBα degradation.
2026. júl. 1.· Journal of advanced research· PUBMED
Publikáció
Immune checkpoint LAG-3 governs stage-dependent and disease-associated microglial modules in ALS model mice.
2026. jún. 25.· Journal of neuroinflammation· PUBMED
Publikáció
Tumor-infiltrating CD8+Ki-67+ and CD8+LAG-3+ T cells are associated with improved patient survival in retroperitoneal dedifferentiated liposarcomas and leiomyosarcomas.
2026. jún. 17.· Experimental and molecular pathology· PUBMED
Publikáció
Near-Infrared Fluorescent Probes Targeting LAG-3 for Guiding Immunomodulation and Efficacy Monitoring of Stereotactic Body Radiotherapy in Liver Cancer.
2026. jún. 17.· Journal of hepatocellular carcinoma· PUBMED
Publikáció
Immune checkpoint crosstalk between LAG-3 and CD39/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies.
2026. jún. 15.· Journal of the Egyptian National Cancer Institute· PUBMED
Publikáció
Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.
2026. jún. 7.· Transfusion medicine reviews· PUBMED
Publikáció
Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity.
2026. jún. 2.· Signal transduction and targeted therapy· PUBMED
Publikáció
NK Cell Profiling: Expression of TIGIT and LAG3 as Immune Checkpoints in Advanced Endometriosis.
2026. jún. 1.· American journal of reproductive immunology (New York, N.Y. : 1989)· PUBMED
Publikáció
Elevated Allele Frequency of a Common Germline LAG3 Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid Leukemia.
2026. máj. 21.· Cancers· PUBMED
Publikáció
Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer.
2026. máj. 15.· Cancer research· PUBMED
Publikáció
Immune receptor LAG3 regulates microglia function during Alzheimer's disease.
2026. máj. 12.· Neurobiology of disease· PUBMED
Preprint
Immune receptor LAG3 regulates microglia function during Alzheimer's disease.
2026. máj. 12.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
A Potent Single-Domain Antibody Targeting LAG-3 for Efficient Tumor Immunotherapy.
2026. máj. 4.· Current issues in molecular biology· PUBMED
Publikáció
LAG3 as a potential biomarker in breast cancer: integrated tissue and peripheral blood analysis reveals clinical and pathomic insights in triple-negative disease.
2026. ápr. 27.· Journal of translational medicine· PUBMED
Publikáció
Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.
2026. ápr. 23.· International journal of cancer· PUBMED
Publikáció
Elevated soluble LAG-3 in chronic hepatitis B and T-cell responses to checkpoint blockade.
2026. ápr. 22.· Antiviral research· PUBMED